Oxford, United Kingdom, 07 March, 2022: Orbit Discovery (Orbit), a ground-breaking peptide discovery company is pleased to announce the commencement of a partnership with WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry. Orbit will combine its leading peptide discovery platform and experience with WuXi […]

Oxford, UK – July 20, 2021 – Orbit Discovery Ltd., (“Orbit”), a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, today announced that it has raised $7.6 million in funding. The financing was led by Oxford Sciences Innovation, with participation from Borealis Ventures, Perivoli Innovations, […]

Oxford, United Kingdom, June 29, 2021: Orbit Discovery Ltd (“Orbit”), a biopharmaceutical company focused on discovering candidate peptide therapeutics using high throughput microfluidic platforms, has announced the appointment of Dr Neil Butt as Chief Executive Officer. With an extensive track record in commercialising proprietary drug discovery platforms, Dr Butt joins Orbit to oversee the Company’s […]

Oxford, UK: 30th August 2019 Orbit Discovery, an Oxford, UK-based biotech company developing an industry-leading peptide discovery platform, are pleased to announce that Dr Mario Polywka has joined their board as a non-executive director. Mario Polywka brings exceptional operational, commercial and strategic development experience to Orbit Discovery. He retired as Chief Operating Officer of Evotec […]